Consort Medical plc (LON:CSRT)‘s stock had its “buy” rating reissued by research analysts at Stifel Nicolaus in a research note issued to investors on Thursday. They presently have a GBX 1,250 ($16.44) price objective on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 12.07% from the company’s current price.
Consort Medical plc (LON:CSRT) traded down GBX 0.60 ($0.01) during trading hours on Thursday, hitting GBX 1,115.40 ($14.67). 11,181 shares of the stock traded hands, compared to its average volume of 32,346. Consort Medical plc has a 12-month low of GBX 960 ($12.63) and a 12-month high of GBX 1,129 ($14.85).
ILLEGAL ACTIVITY NOTICE: “Consort Medical plc (CSRT) Rating Reiterated by Stifel Nicolaus” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/11/11/consort-medical-plc-csrt-rating-reiterated-by-stifel-nicolaus.html.
Consort Medical plc Company Profile
Consort Medical PLC is a contract development and manufacturing organization (CDMO). The Company’s principal activities include designing, development and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The Company operates through two segments: Bespak and Aesica.
Receive News & Ratings for Consort Medical plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical plc and related companies with MarketBeat.com's FREE daily email newsletter.